ASCO 2021: Telaglenastat plus cabozantinib for metastatic kidney cancer
Cell metabolism in renal cell carcinoma (RCC) tumours is disrupted, [...]
Cell metabolism in renal cell carcinoma (RCC) tumours is disrupted, [...]
Results from the phase 3 CLEAR study were presented at [...]
The cabozantinib/nivolumab combination has been shown to be effective at [...]
Adjuvant therapy is medication that is given in addition to [...]
Circulating tumour cells in the blood of cancer patients are [...]